Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Per the data readout, treatment with ARCT-154 showed a stronger and longer-lasting immune response compared with that achieved with the conventional mRNA vaccine, Comirnaty, developed jointly by ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

According to The People’s Vaccine Alliance, Comirnaty costs an estimated $1.18 per dose to produce. For over two years now, the US government has been running its public vaccination campaign ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY Omicron XBB.1.5? COMIRNATY Omicron XBB.1.5 is a vaccine given to prevent coronavirus disease ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...

Pfizer Inc. (NYSE: PFE) has reported a robust financial performance for the third quarter of 2024, showcasing significant ...